S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
APVO · Aptevo Therapeutics Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Aptevo Therapeutics Inc (APVO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.63
+0.00
(+0.00%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.63
$1.62
$1.63
52-WEEK RANGE
$1.63
$1.37
$29.70
What's happening
- APVO is up 0.00% today, trading at $1.63. — Live quote
- It's trading within 3% of its 52-week low ($1.37). (Finnhub fundamentals)
- Volume today (523) is well below its 3-month average of 89,110. (Finnhub fundamentals)
- Reports earnings on 2026-11-04, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-5.31 actual vs. $-6.14 estimated (+13.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
APVO
-82.87%
vs S&P 500
-95.65%
1-YEAR RETURN
APVO
-94.46%
vs S&P 500
-109.02%
6-MONTH RETURN
APVO
-71.21%
3-MONTH RETURN
APVO
-63.46%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-5.31
Est. $-6.14
BEAT +13.5%
2026-04-26 (Q1 2026)
$-6.41
Est. $-5.71
MISS -12.2%
2026-01-26 (Q4 2025)
$-0.01
Est. $-8.25
BEAT +99.9%
2025-10-26 (Q3 2025)
$-33.48
Est. $-38.37
BEAT +12.7%
Valuation Measures & Ratios
Enterprise Value4-$6.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.23
Price / Book70.92
EV4 / Revenue-0.53
EV4 / EBITDA-0.94
Profit Margin-222.55%
Operating Margin-154.97%
Return on Equity (ROE8)-201.49%
Return on Assets (ROA9)-119.21%
Avg Volume (3M)89,110
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.7M | $147.6K | $2.9M | $74.6K | $55.9K |
| P/E | -0.07 | -0.01 | -0.12 | -0.00 | -0.00 |
| Price/Book | 0.29 | 0.01 | 0.17 | 0.01 | -0.04 |
| EV/EBITDA | 0.30 | 0.53 | 0.72 | — | — |
| ROE | -443.73% | -231.30% | -145.25% | -361.68% | 1644.67% |
| ROA | -184.63% | -134.95% | -93.58% | -151.02% | -290.41% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short119,457
Change from Prior Settlement-36.44%
% of Float—
Days to Cover (Short Ratio)1.71
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -222.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -94.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on APVO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$6.4M | -$6.8M | -$7.6M | -$6.2M | -$6.5M | -$5.2M | -$6.0M | -$7.0M |
| Net income | -$6.4M | -$6.7M | -$7.5M | -$6.2M | -$6.4M | -$5.1M | -$5.9M | -$6.8M |
| EPS (diluted) | $-5.31 | $-6.41 | $-2.23 | $-151.29 | $-1581.81 | $-357.86 | $-1236.96 | $-368.21 |
| EPS (basic) | $-5.31 | $-6.41 | $-2.23 | $-151.29 | $-1581.81 | $-357.86 | $-1236.96 | $-368.21 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $14.5M | $19.9M | $27.2M | $27.0M | $15.6M | $8.3M | $15.6M | $15.1M |
| Total liabilities | $8.5M | $8.3M | $9.8M | $9.6M | $9.1M | $9.8M | $10.8M | $10.7M |
| Stockholders' equity | $6.0M | $11.6M | $17.4M | $17.4M | $6.5M | -$1.5M | $4.8M | $4.4M |
| Total current assets | $10.8M | $16.0M | $23.1M | $22.6M | $11.1M | $3.6M | $10.7M | $10.0M |
| Total current liabilities | $5.2M | $4.8M | $6.0M | $5.6M | $4.9M | $5.4M | $6.2M | $5.9M |
| Cash & equivalents | $9.8M | $14.5M | $21.6M | $21.1M | $9.4M | $2.1M | $8.7M | $7.8M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | $462.0K | $851.0K | $853.0K | $77.0K | $82.0K | $120.0K | $1.0M | $624.0K |
| Property, plant & equipment | $236.0K | $268.0K | $303.0K | $384.0K | $432.0K | $482.0K | $543.0K | $614.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $1.2M | $890.0K | $877.0K | — | — | — | $1.2M | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | $1.5M | $948.0K | $1.1M | $1.3M | $1.4M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $14.0K |
| Common stock & paid-in capital | $114.0K | $114.0K | $114.0K | $110.0K | $99.0K | $84.0K | $84.0K | $82.0K |
| Retained earnings | -$288.3M | -$281.9M | -$275.1M | -$269.2M | -$260.2M | -$254.0M | -$247.6M | -$241.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.5M | -$8.0M | -$5.2M | -$6.7M | -$7.1M | -$6.6M | -$5.8M | -$5.2M |
| Investing cash flow | $0 | $0 | $0 | — | $0 | $0 | $0 | — |
| Financing cash flow | $726.0K | $871.0K | $5.8M | $18.3M | $14.4M | $0 | $6.7M | $4.9M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $32.0K | $35.0K | $81.0K | $49.0K | $49.0K | $61.0K | $71.0K | $84.0K |
| Share-based compensation | $58.0K | $57.0K | $2.0K | $77.0K | -$163.0K | $180.0K | -$72.0K | $149.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | $272.0K | $13.0K | — | — | -$936.0K | $278.0K | — | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | $0 | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.1M | $12.3M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M | -$28.5M |
| EPS (diluted) | $-87.27 | $-31460.23 | $-2316.83 | $1.57 | $-6.07 |
| EPS (basic) | $-87.27 | $-31460.23 | $-2316.83 | $1.57 | $-6.07 |
| Operating margin | — | — | — | -$920 | -$174 |
| Net margin | — | — | — | $258 | -$232 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M |
| Stockholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M |
| Total current assets | $23.1M | $10.7M | $19.1M | $27.4M | $52.6M |
| Total current liabilities | $6.0M | $6.2M | $7.2M | $8.7M | $34.8M |
| Cash & equivalents | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Other current assets | $853.0K | $1.0M | $689.0K | $744.0K | $780.0K |
| Property, plant & equipment | $303.0K | $543.0K | $895.0K | $1.5M | $2.4M |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | $68.0K |
| Accounts payable | $877.0K | $1.2M | — | — | — |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | $2.0M | $11.7M |
| Other current liabilities | — | $1.3M | $1.1M | $1.1M | $2.1M |
| Long-term debt | — | — | $0 | $4.0M | $16.0M |
| Other non-current liabilities | — | $0 | — | — | — |
| Common stock & paid-in capital | $114.0K | $84.0K | $61.0K | $48.0K | $47.0K |
| Retained earnings | -$275.1M | -$247.6M | -$223.4M | -$206.0M | -$214.1M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M |
| Investing cash flow | $0 | $0 | $0 | -$29.0K | -$713.0K |
| Financing cash flow | $38.5M | $15.6M | $6.0M | -$2.6M | $26.2M |
| Free cash flow | — | — | — | -$21.1M | -$22.4M |
| Capital expenditures | — | — | — | $29.0K | $713.0K |
| Depreciation & amortization | $240.0K | $352.0K | $567.0K | $901.0K | $1.1M |
| Share-based compensation | $96.0K | $1.1M | $2.2M | $1.8M | $1.6M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — |
| Change in inventory | — | — | — | — | — |
| Purchases of investments | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | $0 | $3.5M | $12.3M | $10.6M |
| Tax withholding on stock comp | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding APVO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-07-17 to 2026-08-06
Recent transactions
- Most recent: Harsanyi Zsolt (Reporting person) — Option exercise of 400 shares on 2026-08-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Harsanyi Zsolt | Reporting person | Option exercise | 2026-08-06 | 400 |
| Lamothe Jeffrey G. | President and CEO | Option exercise | 2026-08-06 | 961 |
| Taylor Daphne | SVP, CFO | Option exercise | 2026-08-06 | 638 |
| Kwon SoYoung | SVP, GC, BD & Corp Affairs | Option exercise | 2026-08-06 | 638 |
| Huebner Dirk | SVP, CMO | Option exercise | 2026-08-06 | 638 |
| Grant Grady III | Reporting person | Option exercise | 2026-08-06 | 400 |
| White Marvin L | Executive Chair | Option exercise | 2026-08-06 | 1,666 |
| Abdun-Nabi Daniel | Reporting person | Option exercise | 2026-08-06 | 400 |
| Kunz Barbara Lopez | Reporting person | Option exercise | 2026-08-06 | 400 |
| Niederhuber John | Reporting person | Option exercise | 2026-08-06 | 400 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-06 | Harsanyi Zsolt | Reporting person | Option exercise | 400 | — |
| 2026-08-06 | Lamothe Jeffrey G. | President and CEO | Option exercise | 961 | — |
| 2026-08-06 | Taylor Daphne | SVP, CFO | Option exercise | 638 | — |
| 2026-08-06 | Kwon SoYoung | SVP, GC, BD & Corp Affairs | Option exercise | 638 | — |
| 2026-08-06 | Huebner Dirk | SVP, CMO | Option exercise | 638 | — |
| 2026-08-06 | Huebner Dirk | SVP, CMO | Tax withholding | 156 | $4.07 |
| 2026-08-06 | Grant Grady III | Reporting person | Option exercise | 400 | — |
| 2026-08-06 | White Marvin L | Executive Chair | Option exercise | 1,666 | — |
| 2026-08-06 | White Marvin L | Executive Chair | Tax withholding | 406 | $4.07 |
| 2026-08-06 | Abdun-Nabi Daniel | Reporting person | Option exercise | 400 | — |
| 2026-08-06 | Kunz Barbara Lopez | Reporting person | Option exercise | 400 | — |
| 2026-08-06 | Niederhuber John | Reporting person | Option exercise | 400 | — |
| 2026-07-17 | White Marvin L | Executive Chair | Option exercise | 1 | — |
| 2025-11-10 | Grant Grady III | Reporting person | Open market purchase | 13,513 | $1.49 |
| 2025-07-17 | Harsanyi Zsolt | Reporting person | Option exercise | 1 | — |
| 2025-07-17 | Kunz Barbara Lopez | Reporting person | Option exercise | 1 | — |
| 2025-07-17 | Abdun-Nabi Daniel | Reporting person | Option exercise | 1 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-09-24 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-03 | 8-K | 2026-09-03 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-21 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
Recent news
Headlines about APVO (Aptevo Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
APVO 8-K & SEC Filings
Yahoo Finance · 2026-10-15 -
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Yahoo · 2026-10-14 -
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Yahoo Finance · 2026-09-24 -
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
Yahoo Finance · 2026-09-03 -
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Yahoo Finance · 2026-09-03 -
APVO: Focusing on Three Key Areas of Development
Yahoo Finance · 2026-08-24 -
Aptevo Therapeutics reports Q2 results
Seeking Alpha · 2026-08-14 -
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Yahoo Finance · 2026-08-14
No headlines in this category right now — try “All”.